Committee for Medicinal Products for Human Use (CHMP) recommend addition of a new pharmaceutical form of daratumumab (Darzalex)

CHMP recommend addition of a solution for injection associated with a new strength (1800 mg in 15ml vial) and new route of administration (subcutaneous injection). New formulation can be used for all existing licensed indications e.g. treatment of multiple myeloma.

Source:

European Medicines Agency